Effect of Entecavir Combined with Adefovir Dipivoxil on Clinical Efficacy and TNF-α and IL-6 Levels in Patients with Hepatitis B Cirrhosis.

Yonghuan Yu,Baofeng Ren,Jingjing Zhao,Xiaoyan Zhang,Ting Jia,Xinfeng Cui

doi:10.1155/2021/9162346

Abstract

Objective The purpose of the study was to investigate the effect of entecavir combined with adefovir dipivoxil on clinical efficacy and TNF-α and IL-6 levels in patients with hepatitis B cirrhosis. Methods A total of 100 patients with hepatitis B cirrhosis admitted to our hospital between January 2018 and June 2019 were randomly selected and divided into the control group (n = 50) and experimental group (n = 50) according to the order of admission. Among them, the control group patients were treated with entecavir, while the patients in the experimental group received entecavir combined with adefovir dipivoxil. After that, the effective rate of treatment, the incidence of adverse reactions, liver function indexes, liver fibrosis condition, and TNF-α and IL-6 expression levels were all compared between the two groups. Results The effective rate of treatment in the experimental group was significantly higher than that in the control group, with statistical significance (p < 0.001); the incidence of adverse reactions of the patients in the experimental group was significantly lower than that in the control group, with statistical significance (p < 0.001); the liver function indexes in the experimental group were significantly better than those in the control group, with statistical significance (p < 0.001); the number of patients with liver fibrosis in the experimental group was significantly less than that in the control group, with statistical significance (p < 0.001); the TNF-α and IL-6 expression levels in the experimental group were significantly lower than those in the control group, with statistical significance (p < 0.001). Conclusion Entecavir combined with adefovir dipivoxil in the treatment of hepatitis B cirrhosis can effectively improve the therapeutic effect and reduce the serum inflammatory factor levels, with high safety, which is worthy of application and popularization.

Highlights

Hepatitis B cirrhosis refers to clinically common chronic liver cirrhosis caused by hepatitis B, which poses a great threat to people’s daily life [1]
Anti-infection, and anti-hepatitis B virus (HBV) functions, drugs such as entecavir and adefovir dipivoxil are commonly used for hepatitis B cirrhosis, and their main components were guanine nucleoside analogues, which can inhibit hepatitis B polymerase and have been confirmed in the treatment of chronic hepatitis B [16]
Our study results showed that the effective rate of treatment in the experimental group was significantly higher than that in the control group, with statistical significance (p < 0.05), indicating that entecavir combined with adefovir dipivoxil can greatly improve the therapeutic effect

Summary

Introduction

Hepatitis B cirrhosis refers to clinically common chronic liver cirrhosis caused by hepatitis B, which poses a great threat to people’s daily life [1]. Liver fibrosis refers to the pathological process of abnormal hyperplasia of connective tissue in the liver, which is an important factor affecting the prognosis of chronic liver disease. Clinical trials have found that patients with hepatitis B cirrhosis may show liver fibrosis and increased expression levels of serum inflammatory factors during treatment, leaving them in a microinflammatory state for a long time and affecting the therapeutic effect [5]. Adefovir dipivoxil, and lamivudine, with antibacterial and antivirus effects, are common and effective clinical drugs to treat liver cirrhosis [6].

Methods

Results

Conclusion